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INTRODUCTION
Relapsed disease remains a major limitation to success-
ful allogeneic BMT. Second allogeneic transplantation may
cure a small number of patients with recurrent disease, but it
does so at the expense of extensive morbidity and mortality
[1,2]. Donor leukocyte infusions are an effective alternative
therapy for patients who relapse after allogeneic BMT
[3–10]. The graft-vs.-leukemia (GVL) effect associated with
DLI is most evident in patients with relapsed CML in
chronic phase: 60–80% of these patients reenter complete
remission (CR) after DLI [4,5,11]. DLI also is effective for
patients who relapse with other hematologic malignancies,
but remission rates are lower [4,5,12]. DLI is safer and at
least as effective as a second allogeneic BMT and therefore
is being used with increasing frequency for patients who
relapse after transplantation. Furthermore, new clinical tri-
als are being developed using preemptive DLI after
T cell–depleted marrow grafting in an attempt to restore
lost GVL activity. 
The durability of DLI-induced remissions and the long-
term survival after DLI has not been well established, how-
ever. In one large retrospective series of DLI, four of 33
patients (12%) who achieved a CR from DLI for recurrent
CML subsequently relapsed [4]. The median remission dura-
tion for six acute myelogenous leukemia (AML) patients who
entered CR after DLI was 17.9 months, with four of six
patients ultimately relapsing. Similar relapse rates were
reported by the European Blood and Marrow Transplanta-
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ABSTRACT
Donor leukocyte infusions (DLI) can induce a direct graft-vs-leukemia (GVL) reaction and restore complete remis-
sion for patients who relapse after allogeneic bone marrow transplantation (BMT). A critical and unanswered con-
cern is the long-term safety and durability of DLI. To determine remission duration, long-term toxicity, and survival
after DLI-induced remissions, we identified 73 patients who achieved complete remission after DLI. Follow-up
information was obtained for 66 of the 73 patients, including 39 patients with chronic myelogenous leukemia
(CML) and 27 patients with other diseases. Median follow-up for all patients was 32 months; the probability of sur-
vival at 1, 2, and 3 years was 83% (95% confidence interval [CI] 74–92), 71% (60–83), and 61% (49–74), respectively.
For CML, survival probability at 1, 2, and 3 years was 87% (76–98), 76% (62–90), and 73% (58–88). For other dis-
eases, survival probability at 1 and 2 years is 77% (61–93) and 65% (46–84). Five of 39 patients with CML relapsed,
and 11 of 27 patients with other diseases relapsed. Treatment-related toxicity accounted for 10 deaths. Extended
follow-up shows that DLI-induced remissions are durable, especially for patients with CML. Late relapses still
occur, however, and toxicity remains significant. Continued follow-up will best define the long-term GVL effects of
DLI, especially for diseases other than CML.
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tion Group (EBMT) [5]. They also described significant late
mortality after DLI; that retrospective analysis noted an
actuarial probability of death in remission at 1 year after DLI
of 18% for patients with CML or polycythemia vera, 10%
for patients with AML/myelodysplasia (MDS), and 5% for
patients with acute lymphocytic leukemia (ALL). 
Longer follow-up is needed to assess the overall impact of
DLI on disease-free and overall survival. These data are criti-
cal to establish the role of DLI in the treatment of relapse and
in the design of trials using prospective DLI to overcome the
high relapse rate in T cell–depleted transplantation. There-
fore, we obtained follow-up data on patients who achieved a
CR after DLI and who were included in a large multicenter
retrospective analysis. We analyzed long-term outcomes in
this cohort to determine remission duration, long-term toxic-
ity, event-free survival, and overall survival. 
METHODS
Patients and data collection
Patients who achieved CR after DLI were identified
through data submitted to a multicenter North American
database [4] (also unpublished data). Data from 214 patients
treated at 58 institutions were available in this database by
24 May 1997 when questionnaires were distributed. Data
were collected retrospectively in 195 patients and prospec-
tively for 19 patients. Seventy-three patients were identified
who were in CR after DLI. Questionnaires were sent to the
treating physicians to assess long-term outcome, including
incidence of relapse, incidence of graft-vs.-host disease
(GVHD), current disease status (including death and cause
of death), effect of therapy for relapse, and long-term sur-
vival. Long-term follow-up data were collected from 66 of
73 identified patients (90%). Patient characteristics are
shown in Table 1. Details about initial transplant, relapse,
and DLI therapy have been reported previously for most of
these patients [4].
Definitions
Fifty-one patients achieved a CR directly from DLI
(with or without the use of cytokines such as interferon),
and 15 patients were considered not evaluable for a response
to DLI because donor cells were administered when patients
were in CR after salvage chemotherapy (11 patients) or at
the time of a chemotherapy-induced blood count nadir (four
patients). 
Patient data were grouped into two categories, CML
or other diseases, based on previously published series.
Thirty-nine patients had CML and 27 patients had AML,
ALL, MDS, myeloma, CLL, or NHL. Patients were con-
sidered to have early-phase relapse of CML if they were
treated for molecular, cytogenetic, or chronic-phase
relapse. Patients were considered to have late-phase
relapse of CML if they were treated with DLI for acceler-
ated-phase or blast-crisis CML.
For patients with CML, CR was defined as a cytogenet-
ic remission (no detectable Ph+ cells). One patient received
DLI while in cytogenetic remission but had evidence of dis-
ease by polymerase chain reaction (PCR) for bcr/abl m-RNA
(molecular relapse); a CR in this patient was defined as a
molecular remission with no detectable CML cells by PCR
analysis. Some patients had evidence of CML recurrence
after DLI-induced remission by PCR analysis only (molecu-
lar relapse); these patients were not scored as a relapse after
DLI unless and until they had evidence of at least cytoge-
netic relapse. 
A complete remission in patients with diseases other
than CML was determined by morphologic evaluation of
the peripheral blood and bone marrow by the patient’s treat-
ing physician in all but two patients, who did not have bone
marrow results documented. All patients with cytogenetic
abnormalities had normal results of cytogenetic studies as
further documentation of complete remission. 
Statistical analysis
Data were analyzed on a Unix computer (RISC System
6000, IBM France) either at the computer center of Tel Aviv
University with a BMDP (Biomedical Computer Programs;
University of California, Berkeley, CA) and SPSS statistical
software package (Chicago, IL) or with a Statview statistical
software package (Abacus Concepts, Berkeley, CA) at the
University of Pennsylvania. Differences in categorical vari-
ables (such as relapse rate) between groups were tested (or
detected) using the x2 test. The probability of survival and
event-free survival (EFS) were calculated according to the
Table 1. Characteristics of the 66 patients studied
Diagnosis
CML 39
Other 27
AML 15
ALL 4
Myelodysplasia 3
Myeloma 3
CLL 1
NHL 1
Median age (years) 35 (range 10–61)
Sex
Female 35 (53%)
Male 31 (47%)
Donor sex
Matched 35 (53%)
Mismatched 29 (44%)
Not known 2 (3%)
Donor relationship
Matched sibling 59
Mismatched sibling 2
Matched unrelated 4
Mismatched unrelated 1
Transplant graft
T cell–depleted 28 (42%)
T cell replete 38 (58%)
Acute GVHD after transplant
Grade 0 38 (58%)
Grade I 18 (27%)
Grade II 10 (15%)
Grade III or IV 0 (0%)
Chronic GVHD after transplant
None 50 (76%)
Limited 15 (23%)
Extensive 1 (2%)
CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma.
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method of Kaplan and Meier [13], and the differences
between them were analyzed according to the generalized
Wilcoxon (Breslow) test [14]. For the purpose of this analy-
sis, an event was defined as relapse or death from any cause.
Overall survival was calculated from the time of first DLI
until death or last follow-up, and EFS was calculated from
the time complete remission was documented until relapse,
death, or last follow-up. A stepwise logistic regression analy-
sis was used to assess the odds ratio for survival. The inde-
pendent factors included in the model are patient sex, age,
type of disease (CML vs. others), BMT with T cell–depleted
graft, and development of either acute or chronic GVHD.
The date of last follow-up for this study was November
1997 or the date of last contact with a patient.
RESULTS
Overall survival
All patients. Follow-up data were obtained from 66
patients who achieved CR after DLI. The median time of
follow-up after DLI was 32 months (range 1–70), and the
median time of follow-up after achieving a CR was 30
months (range 1–69). The outcome and follow-up after DLI
are summarized in Table 2. Thirty-nine patients (59%)
remained alive with a median follow-up of 39 months after
DLI (range 4–70); 34 remained in complete remission.
Twenty-seven patients (41%) died, as noted in Table 2.
Thirteen patients (48%) were in remission at the time of
death; 11 (40%) died with active disease, one patient with a
molecular relapse of CML died of non–treatment-related
causes, and disease status was not evaluable at the time of
death in two patients. The overall probability of survival was
83% (95% CI 74–92) at 1 year, 71% (60–83) at 2 years, and
61% (49–74) at 3 years as shown in Figure 1. A significant
survival advantage exists for patients who achieve a CR after
DLI for CML compared with patients who achieve a CR for
non-CML diseases (p = 0.016).
Patients with CML. Follow-up data were obtained from
39 DLI recipients with relapsed CML. Twenty-six (67%)
remained alive with a median follow-up of 40 months (range
4–70); 25 (64%) remained in complete remission (including
two patients who had evidence of minimal residual disease by
molecular analysis), and current disease status is unknown in
one patient. Thirteen patients (33%) died, as shown in Table
2. The overall probability of survival was 87% (76–98) at 1
year, 76% (62–90) at 2 years, and 73% (58–88) at 3 years.
Patients with Non-CML disease. Follow-up data were col-
lected for 27 patients who received DLI for relapse of dis-
eases other than CML. Thirteen of these patients (48%)
remained alive with a median follow-up of 29 months from
Table 2. Long-term outcome for patients in complete remission after DLI
Outcome All patients CML Non-CML
n 66 39 27
Alive
No. patients (%) 39 (59) 26 (67) 13 (48)
Median months 
of follow-up (range) 39 (4–70) 40 (4–70) 29 (7–57)
No. in CR (%) 34 (52) 25 (64)* 11 (41)
Relapse after CR from DLI
No. patients (%) 16 (24) 5 (13) 11 (41)
Median months from CR 
to relapse (range) 6 (1–37) 4 (1–13) 10 (1–37)
Dead
No. patients (%) 27 (41) 13 (33) 14 (52)
Cause of death
Progressive disease 9 4 5
GVHD 7 4 3
Infection 6 1 5
Other or unknown cause 5 4 1
*Includes two patients alive with only molecular evidence of CML.
Figure 1. Probability of survival after DLI
Kaplan-Meier estimate of overall survival in all patients who achieved CR after DLI for relapse after allogeneic bone marrow transplantation. Tick marks indi-
cate censored patients.
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DLI (range 7–57). Eleven patients (41%) remained in CR,
and two patients with ALL were alive with active disease.
Fourteen patients (52%) died, as described in Table 2. Six
patients died while in remission, and seven patients had evi-
dence of disease at death. Disease status was not known at
the time of death in one patient. The overall survival was
77% (61–93) at 1 year and 65% (46–84) at 2 years. 
Overall survival was determined for all patients with a
diagnosis other than CML and compared with overall sur-
vival of patients with a diagnosis of AML and MDS only or
AML, MDS, and ALL only. No significant difference was
found in overall probability of survival among these groups.
Event-free survival
All patients. Relapse occurred in 16 patients (24%) 1–39
months after DLI (median 10 months) and 1–37 months
after CR was documented (median 6 months). Relapse was
treated in 13 of these patients as described below. Three of
the 16 relapsed patients remained alive, two with active dis-
ease and one in spontaneous remission, as noted below. 
EFS was determined from the time of CR for all 66
patients who achieved a CR after DLI. EFS was 69%
(57–81) at 1 year, 60% (47–73) at 2 years, and 58% (45–71)
at 3 years. Although 10 patients in CR at the time of DLI,
and recipients of DLI during a chemotherapy-induced
nadir, were included in this analysis, there was no significant
difference in EFS in any group when those patients were
excluded (data not shown). 
A significant difference in EFS existed for all patients
who achieved a CR after DLI for CML compared with
those who achieved a CR after DLI for non-CML diseases
(p = 0.002), as shown in Figure 2. When patients were
excluded who were not evaluable for a direct response to
DLI because donor cells were given during CR or during a
chemotherapy-induced nadir, a significant EFS advantage
for CML patients (p = 0.002) still existed.
Patients with CML. Five patients with CML (13%)
relapsed 1–13 months after a documented remission (medi-
an 4 months). Relapse was treated in four patients; treat-
ments included chemotherapy (two patients), interferon and
second BMT (one patient), and radiation therapy (one
patient), but no patient achieved a second remission. A sec-
ond course of DLI was not given to any patient. All five
patients with relapsed disease died 1–13 months after
relapse attributable to either progressive disease (four
patients) or an unknown cause (one patient). 
The probability of EFS from time of CR for recipients
of DLI for CML was 79% (66–92) at 1 year and 73%
(58–88) at 2 and 3 years. The actuarial probability of EFS
for these patients is shown in Figure 2.
The initial course of DLI was given for early-phase
relapse of CML in 32 patients (one with molecular relapse,
six with cytogenetic relapse, and 25 with chronic-phase
relapse) and advanced-phase relapse (accelerated phase or
blast crisis) in seven patients. The time from transplant to
relapse was similar in both groups (early-phase relapse 12
months, advanced-phase relapse 13 months). Seven of 32
patients (22%) treated for early-phase relapse died of pro-
gressive disease (two patients), GVHD (two patients), or
other causes (three patients), whereas six of seven (86%)
patients treated for advanced-phase relapse died of progres-
sive disease (two patients), GVHD (two patients), or other
causes (two patients). Disease subsequently recurred after
DLI in two of 32 patients (6%) treated for early-phase
relapse and three of seven patients (43%) treated for
advanced-phase relapse. Treatment for early-phase relapse
compared with advanced-phase relapse was associated with
improved overall survival (p = 0.004) and EFS (p = 0.004).
For the seven patients who entered CR after treatment
for cytogenetic or molecular relapses, six remained alive
without disease, and one died of GVHD. No relapses
occurred in those patients with a median follow-up of 27
Figure 2. Probability of event-free survival in CML patients compared with patients with other diseases
All patients achieved CR after DLI for relapse after allogeneic bone marrow transplantation. Event-free survival in CML patients (solid line) was compared with
that in patients with diagnoses other than CML (dashed line). Event-free survival was measured from time of documented complete remission. Tick marks indi-
cate censored patients.
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months (range 4–43). Of the 25 patients treated for chronic-
phase relapse, two (8%) relapsed and six (24%) died. Three
patients in CR after DLI, documented by cytogenetic and
molecular analyses, had recurrent disease detectable only by
PCR. One patient died of another malignancy without pro-
gression of disease, and two patients remained alive with
minimal disease detectable only by molecular PCR analysis.
Patients with non-CML disease. Of the 27 recipients of
DLI for diseases other than CML, 11 (41%) relapsed,
including four of 15 with AML, three of four with ALL, two
of three with myeloma, one of three with MDS, and one of
one with NHL. The time from remission to relapse was
1–37 months (median 10 months). Relapse was treated in
nine patients with standard chemotherapy, in one with high-
dose chemotherapy, and in one with second BMT. Two of
those patients achieved remission but subsequently relapsed.
A second course of DLI was not given to any patient. Of the
11 patients, eight died, one patient with myeloma entered a
spontaneous remission, and two patients with ALL
remained alive with active disease.
The probability of EFS for the entire group was 52%
(32–72) at 1 year, 38% (18–58) at 2 years, and 31% (11–51)
at 3 years (Fig. 2). The EFS for the 10 patients with AML,
MDS, and ALL who were evaluable for a direct response to
DLI was 58% (26–90) at 1 year and 47% (14–80) at 2 years. 
Effect of pre-DLI therapy
Fifteen patients received donor cells either after achiev-
ing a complete remission (11 patients) or at the time of a
chemotherapy-induced nadir (four patients). One patient
with CML received chemotherapy before DLI and, in
remission, died 1.4 months later of unknown causes. Of the
remaining 14 patients, 10 had AML, one had multiple
myeloma, one had ALL, one had MDS, and one had CLL.
The median follow-up for this cohort of 14 patients was 17
months (range 1–41), and the estimated median survival was
~32 months from DLI. The outcome for these patients
compared with that of 13 patients who had a direct response
to DLI is shown in Table 3. Five (36%) subsequently
relapsed at a median of 12 months after DLI (range 1–39).
Six patients (five with AML, one with multiple myeloma)
remained alive in complete remission at a median time of 20
months from DLI (range 7–39).
Thirteen patients had a CR directly attributable to DLI,
including five patients with AML, two with MDS, two with
myeloma, three with ALL, and one with NHL. The median
follow-up for this group of patients was 29 months from DLI
(range 3–57), and the estimated median survival was 35
months. Six (46%) have relapsed a median of 8 months after
DLI (range 3–38). Three of the six relapsed patients died, two
of progressive disease and one of complications of second
BMT; the other three patients remained alive, two with active
disease and one in spontaneous remission. Three patients
died in remission, two from infection and one from GVHD.
Seven patients remained alive 14–57 months after DLI
(median 36 months), five in CR and two with active disease. 
No significant difference was found in relapse rate, time
to relapse, or cause of death based on pre-DLI therapy.
There is no significant difference in the probability of over-
all survival based on pre-DLI therapy (p = 0.39).
Influence of T cell depletion on outcome after DLI
It was hypothesized that recipients of T cell–depleted
grafts for initial transplantation might have a better out-
come after DLI; individuals who relapse after T cell–replete
BMT may be relatively resistant to the GVL effects of
donor T cells. We found no influence on overall survival or
subsequent relapse rate for patients who achieved a CR after
DLI according to T cell content at BMT, however, regard-
less of the underlying diagnosis. 
Association of GVHD with outcome
Acute GVHD occurred after DLI in 52 patients (79%);
grade I acute GVHD occurred in 15 patients, grade II in 17,
grade III in 13, and grade IV in seven. There was no differ-
ence between those who developed or did not develop acute
GVHD after DLI in relapse rate (p = 0.7), EFS (p = 0.9), or
overall survival (p = 0.4).
Chronic GVHD occurred in 48 of 59 of evaluable
patients (81%) and was limited in 26 and extensive in 22.
No association was found between the development of
chronic GVHD and relapse (p = 0.9), EFS (p = 0.17), or
overall survival (p = 0.3). 
Multivariate analysis of factors influencing survival
Factors that were evaluated in a stepwise regression
model for their influence on survival included patient sex,
age, development of acute GVHD, development of chronic
GVHD, and diagnosis (CML vs other). Two independent
risk factors for worse survival were identified, namely,
female sex (odds ratio 2.49, p = 0.05) and a diagnosis other
than CML (odds ratio 2.15, p = 0.02).
DISCUSSION
Relapsed leukemia remains a major cause of treatment
failure after allogeneic BMT, and treatment options for
relapse are limited. A minority of patients may be cured
after second allogeneic BMT, but the anticipated outcome is
disappointing [1,2,15]. Some patients achieve complete
Table 3. Outcome for non-CML patients in CR after DLI based on pre-DLI
therapy
Not evaluable* Direct DLI-induced CR
n 14 13
Relapse after CR 5 (36%) 6 (46%)
Median months to relapse (range) 12 (1–39) 8 (3–38)
Alive in CR 6 (43%) 5 (38%)
Dead 8 (57%) 6 (46%)
Cause of death
Progressive disease 3 (37%) 2 (33%)
GVHD 2 (25%) 1 (16%)
Infection 3 (37%) 2 (33%)
Other/unknown 0 (0%) 1 (16%)
Median months of follow-up 
after DLI (range) 17 (1–41) 29 (3–57)
*Patients were not evaluable for response if DLI was given at the time of com-
plete remission or after cytoreductive chemotherapy but before hematopoietic
recovery.
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remission after standard chemotherapy, granulocyte colony-
stimulating factor (G-CSF) [16], or interleukin-2 therapy
[6]; unfortunately, these approaches are unlikely to result in
long-term cure [17]. Some patients with CML who relapse
after allogeneic BMT may derive significant benefit from
IFN- a [18,19], and patients with cytogenetic relapse are
most likely to experience a complete cytogenetic remission
[20]. However, many of these patients continue to have
detectable bcr/abl gene transcripts, suggesting that they may
eventually relapse. 
Donor leukocyte infusions can provide a direct GVL
reaction and offer an effective approach to relapse that is safer
than second BMT, although long-term follow-up has been
relatively limited. Complete remissions are achieved in
60–80% of patients with relapsed CML and 10–20% of
patients with relapsed acute leukemia [4,5,11]. In a previous
study, we reported survival data in 140 patients with a median
follow-up of 194 days for all patients; median follow-up was
17 months in 53 patients alive at the time of the analysis [4].
It is clear, however, that late relapses occur after DLI-induced
remissions, and toxicity may be significant. To better define
the role of DLI for relapse after allogeneic BMT, we identi-
fied all patients who achieved a CR after DLI whose data
were reported to this North American multicenter group reg-
istry and obtained longer follow-up data. The median follow-
up for surviving patients is 39 months (range 4–70). 
Our data confirm that the GVL effects of donor lym-
phocytes extend at least for several years in many patients.
More than half of all complete responders treated with DLI
for relapsed disease remained alive in CR with a median fol-
low-up of more than 3 years. Fifty-nine percent of patients
treated with DLI for relapsed CML were alive with either
no evidence of disease or minimal residual disease detectable
only by PCR a median of 40 months after DLI. Forty-four
percent of complete responders to DLI for AML or MDS
were alive in remission a median of 28 months after DLI.
Only one of four patients in remission after DLI for ALL
remains in remission, and two of five patients with other
diseases are alive in CR with a minimum follow-up of 19
months after DLI. 
These data also confirm that patients entering remission
with DLI for early-phase relapse of CML are less likely to
have recurrences than are patients treated for advanced-
phase relapse (6 vs. 43%), supporting recommendations to
treat patients early in the course of relapse [21]. Further-
more, no relapses were seen in seven patients treated for the
presence of only cytogenetic or molecular disease with a
median follow-up of more than 2 years. DLI should there-
fore be considered in patients with CML at the time of
detectable minimal residual disease. It should be noted,
however, that because these patients were treated while they
had minimal disease burdens, it may take more time before
relapses become apparent. Therefore, longer follow-up will
ultimately determine the durability of these remissions. 
Notably, 24% (16 of 66) of patients relapsed 1–37
months after entering CR as shown in Table 2. These data
demonstrate that late relapses may occur after DLI. For the
purpose of this analysis, patients with CML were considered
to have relapsed if they had achieved a cytogenetic remis-
sion and then developed recurrent evidence of disease by
cytogenetic analysis. Patients with only molecular evidence
of disease by PCR analysis were not considered to have
relapsed because the significance of minimal residual disease
detected by PCR alone is of unclear significance in CML.
After allogeneic BMT, sequential positive PCR tests predict
clinical relapse, although some patients have evidence of
residual disease by PCR and do not relapse [1,22,23]. It is
notable, however, that a molecular relapse occurred almost 4
years after documented remission, raising a concern that the
GVL effect is not sustained in some patients. The latest
nonmolecular relapse occurred 13 months after CR for
patients with CML and 37 months after CR for a patient
with ALL.
Although the significance of a positive PCR test after
DLI for CML is not known, we determined the incidence of
molecular relapse–free survival for the 37 evaluable CML
patients by scoring molecular evidence of disease by PCR as
relapse. Initially, four patients had evidence of disease by
PCR alone; two patients remained alive with CML
detectable only by PCR, and one patient died with molecu-
lar evidence of disease from glioblastoma multiforme. A
fourth patient who initially had a molecular relapse quickly
progressed to blast crisis. When the analysis is performed in
this manner, the overall probability of relapse-free survival is
81% at 1 year, 75% at 2 years, and 68% at 3 years. There-
fore, defining relapse by molecular evidence of disease did
not significantly affect the results of this analysis. 
This analysis has several limitations. It involves retro-
spective data collection from 23 transplant centers. Treat-
ment strategies and methods and timing of follow-up were
not standardized. Cytogenetic and PCR analysis were not
performed in a central laboratory, and sensitivities may have
varied among institutions. In addition, for patients with
CML, data regarding evaluation for minimal residual dis-
ease was not always available. Therefore, it is possible that
the likelihood of molecular or cytogenetic relapse would be
higher for patients with CML if analyses were performed on
everyone by a standardized method at frequent defined
intervals. Although it is not known if all patients achieved a
molecular remission, in other series of patients treated with
DLI, 95–100% of patients who were in cytogenetic remis-
sion had no detectable bcr/abl RNA transcripts when studied
by PCR [3–5]. Despite these limitations, these patients are
likely to be a representative population of DLI recipients
because data were collected from 90% of identified patients.
This analysis provides some of the longest follow-up infor-
mation available about remission duration and long-term
toxicity after DLI for patients. 
Although most patients who respond to DLI develop
GVHD [4], for patients who achieved a DLI-induced CR,
GVHD did not correlate with relapse, EFS, or overall sur-
vival. Our analysis is limited to the maximal extent of acute
and chronic GVHD, and data are not available on the dura-
tion of GVHD. For instance, it is possible that patients with
sustained, active GVHD would be less likely to relapse,
whereas patients who have GVHD successfully treated may
also lose GVL reactivity and be at risk of relapse. Conclu-
sions about the association of GVHD with persistent GVL
activity require additional analysis. In addition, we found no
association between the use of T cell–depleted marrow at
time of BMT and survival or relapse after DLI. However,
our analysis is limited to patients who achieved a CR after
Long-term Follow-up After DLI
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DLI, and therefore are likely to represent a selected popula-
tion susceptible to the GVL effects of DLI. It is possible
that recipients of T cell–depleted grafts may be more likely
to respond to DLI in the first place, although our initial data
did not support this conclusion [4].
It is not surprising that in a multivariate analysis, a diag-
nosis of CML was associated with improved overall survival
and EFS after DLI because CML tends to be most influ-
enced by GVL mechanisms. It is unclear why a Kaplan-
Meier estimate of survival favored men compared with
women (p = 0.03, data not shown). There was no significant
difference in acute or chronic GVHD after DLI according
to sex, and women were no more likely than men to receive
grafts from sex-mismatched donors. In addition, the cause
of death (treatment related vs. disease related) was not asso-
ciated with the patient’s sex.
In our analysis, the use of pre-DLI chemotherapy (or
DLI at the time of CR) did not affect the probability of
relapse, the time to relapse, or survival. This does not imply
that pre-DLI chemotherapy is unnecessary; this is a retro-
spective analysis and it is not known how patients were
selected to receive pre-DLI chemotherapy. A prospective
trial is currently underway that will attempt to discern the
role of pre-DLI chemotherapy for patients who relapse after
allogeneic transplantation with acute leukemia. 
Treatment-related mortality remains a major cause of
failure after DLI; up to 20% of patients who receive DLI
for relapsed CML die from direct complications of therapy,
such as GVHD, opportunistic infections, and marrow apla-
sia [11]. Longer follow-up now shows that late complica-
tions continue to limit the success of DLI in a cohort of
patients who achieved a CR from DLI. Fifteen percent (10
of 66) of all patients died from direct treatment-related
causes (Table 2) a median of 11 months (range 1–70) after
DLI; most treatment-related deaths were related to compli-
cations of GVHD or bronchiolitis obliterans. Another 15%
of patients died from causes attributable to relapsed disease,
accounting for 37% of all deaths (Table 2). 
Several treatment strategies currently under investiga-
tion may limit toxicity from DLI and result in improved
outcomes. Innovative approaches attempting to minimize
GVHD toxicity include the use of low-dose donor leuko-
cytes [24], the selective depletion of CD8+ T cells from the
donor product [4,25], or modification of donor T cells with
suicide genes that can attenuate GVHD [26–28]. A prospec-
tive trial is currently underway that attempts to minimize
toxicity from marrow aplasia by administering G-
CSF–mobilized donor progenitor cells as DLI therapy.
Interest also exists in pursuing a strategy of T cell–depleted
allogeneic BMT followed by DLI in an effort to restore lost
GVL activity [29,30]. Furthermore, attempts are being
made to exploit the antitumor potential of donor leukocytes
by using DLI as primary therapy [31] or after nonmyeloab-
lative chemotherapy [32,33]. The long-term GVL effects
supplied by all these strategies require further follow-up,
and caution must be taken in designing future therapies if
the GVL effects of DLI are not sustained or treatment-
related mortality is excessive. Data from this analysis suggest
that administration of donor leukocytes when the patient is
in a minimal disease state stands the best chance of causing a
sustained remission. 
The mechanism underlying GVL reactivity remains elu-
sive, but late relapses after DLI may offer important clues. It
is possible that GVL-reactive cells have a limited life span
and need to be administered more than once. Alternatively,
donor leukocytes may develop tolerance to target antigens.
After allogeneic BMT, immune tolerance may explain why
relapses occur in the setting of persistent mixed chimerism
and why DLI with “naive,” or untolerized, cells induce a
GVL effect. It is also possible that either the leukemic cell
phenotype changes to escape GVL effector mechanisms or
that cells that do not express target antigens for GVL
undergo late expansion because they would not be eliminat-
ed by DLI in the first place. It is notable that no patient
included in this analysis was treated for subsequent relapse
with another course of DLI. A second course of DLI might
be expected to induce CR if GVL effector cells have a limit-
ed life span or develop tolerance, whereas no effect would
be seen if leukemia cells evolve a GVL-resistant phenotype.
Ultimately, identification of the GVL effector cells and tar-
get antigens is necessary to understand why some patients
respond to the initial DLI and others do not and why
relapses still occur several months and years after DLI. 
The use of DLI for relapse after allogeneic BMT clearly
offers significant advantages over second allogeneic transplan-
tation in terms of both initial toxicity and relapse rates.
Longer follow-up now shows that DLI-induced remissions
are sustained in many patients, especially when DLI is admin-
istered for relapsed CML. Whether DLI is curative remains
uncertain, however; late relapses still occur, and treatment-
related toxicity is significant. Patients who relapse after allo-
geneic BMT with CML may benefit from IFN- a therapy,
and it is unclear from our analysis if DLI offers an advantage
over IFN- a . At least for CML, however, DLI appears to
induce a higher rate of molecular remissions; ultimately, a
randomized trial of IFN vs. DLI for relapsed CML may be
required. Patients who relapse after BMT for diseases other
than CML have limited treatment options, and initial DLI
may remain the best approach in these patients, although
long-term outcomes remain unsatisfying. New therapies and
continued follow-up of patients who receive DLI after allo-
geneic BMT, either for disease prophylaxis or for relapse, are
required to best define the role of allogeneic DLI.
ACKNOWLEDGMENTS
The following centers contributed to this study by sub-
mitting data: Medical College of Wisconsin (17 patient
records), Brigham and Women’s Hospital (9), Baylor Univer-
sity Medical Center, Dallas (9), Stanford University (3),
Fairview University Medical Center (3), H. Lee Moffitt Can-
cer Center (2), Tufts-New England Medical Center (2), Mayo
Clinic Rochester (2), University of Arizona (2), University of
Kentucky (2), Case Western Reserve (2), University of Pitts-
burgh (2), City of Hope (2), Children’s Hospital of Philadel-
phia (1), University of Nebraska (1), Wayne State University
(1), University of North Carolina (1), University of British
Columbia (1), Johns Hopkins University (1), Rocky Moun-
tain Cancer Center (1), Hahnemann University Hospital (1),
University of Michigan (1), Loyola University (1).
R.H.C. acknowledges support from the Leukemia Asso-
ciation of North Central Texas.
D.L. Porter et al.
260
REFERENCES
1 Radich J, Sanders J, Buckner C, Martin P, Petersen F, Bensinger W,
McDonald G, Mori M, Schoch G, Hansen J: Second allogeneic marrow
transplantation for patients with recurrent leukemia after initial trans-
plant with total-body irradiation-containing regimens. J Clin Oncol
11:304, 1993.
2 Mrsic M, Horowitz M, Atkinson K, Biggs J, Champlin R, Ehninger G,
Gajewski J, Gale R, Herzig R, Prentice H, Rozman C, Sobocinski K, Speck B,
Bortin M: Second HA-identical sibling transplants for leukemia recur-
rence. Bone Marrow Transplant 9:269, 1992.
3 Porter D, Roth M, McGarigle C, Ferrara J, Antin J: Induction of
graft-versus-host disease as immunotherapy for relapsed chronic
myeloid leukemia. N Engl J Med 330:100, 1994.
4 Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R,
Goodman S, Wolff S, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N,
Chetrit A, Antin J, Nemunaitis J: Donor leukocyte infusions in 140
patients with relapsed malignancy after allogeneic bone marrow trans-
plantation. J Clin Oncol 15:433, 1997.
5 Kolb H, Schattenberg A, Goldman J, Hertenstein B, Jacobsen N, Arcese
W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mit-
termueller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect
of donor lymphocyte transfusions in marrow grafted patients. Blood
86:2041, 1995.
6 Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik
J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral
blood cells and recombinant human interleukin-2 to treat leukemia
relapse after allogeneic bone marrow transplantation. Blood 87:2195,
1996.
7 Drobyski W, Keever C, Roth M, Koethe S, Hanson G, McFadden P,
Gottschall J, Ash R, van Tuinen P, Horowitz M, Flomenberg N: Salvage
immunotherapy using donor leukocyte infusions as treatment for
relapsed chronic myelogenous leukemia after allogeneic bone marrow
transplantation: efficacy and toxicity of a defined T-cell dose. Blood
82:2310, 1993.
8 Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M,
Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent
CML after BMT. Bone Marrow Transplant 12:125, 1993.
9 Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze
B, Hubner G, Heimpel H, Arnold R: Interferon-a and donor buffy coat
transfusions for treatment of relapsed chronic myeloid leukemia after
allogeneic bone marrow transplantation. Transplantation 56:1114,
1993.
10 Mackinnon S, Hows J, Goldman J: Induction of in vitro graft-versus-
leukemia activity following bone marrow transplantation for chronic
myeloid leukemia. Blood 76:2037, 1990.
11 Porter D, Antin J: Adoptive immunotherapy in bone marrow trans-
plantation. In: Burakoff S, Deeg H, Ferrara J (eds) Graft-versus-Host-
Disease. New York, Marcel Dekker, 733, 1997.
12 Porter D, Roth M, Lee S, McGarigle C, Ferrara J, Antin J: Adoptive
immunotherapy with donor mononuclear cell infusions to treat relapse
of acute leukemia or myelodysplasia after allogeneic bone marrow
transplantation. Bone Marrow Transplant 18:975, 1996.
13 Kaplan E, Meier P: Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53:457, 1958.
14 Breslow N: Covariance analysis of censored survival data. Biomet-
rics 30:89, 1974.
15 Wagner JE, Vogelsang GB, Zehnbauer BA, Griffin CA, Shah N, San-
tos GW: Relapse of leukemia after bone marrow transplantation: effect
of second myeloablative therapy. Bone Marrow Transplant 9:205, 1992.
16 Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich E, Ander-
son B, O’Brien S, Andreeff M, Fisher H, Cork A, et al.: Preliminary results
of treatment with filgrastim for relapse of leukemia and myelodysplasia
after allogeneic bone marrow transplantation. N Engl J Med 329:757,
1993.
17 Giralt S, Champlin R: Leukemia relapse after allogeneic bone mar-
row transplantation: a review. Blood 84:3603, 1994.
18 Arcese W, Goldman J, D’Arcangelo E, Schattenberg A, Nardi A,
Apperley J, Frassoni F, Aversa F, Prentice H, Ljungman P, Ferrant A,
Marosi C, Sayer H, Niederwieser D, Arnold R, Bandini G, Carreras E,
Parker A, Frappaz D, Mandelli F, Gratwohl A: Outcome for patients who
relapse after allogeneic bone marrow transplantation for chronic
myeloid leukemia. Blood 82:3211, 1993.
19 Higano C, Raskind W, Singer J: Use of alpha interferon for the
treatment of relapse of chronic myelogenous leukemia in chronic phase
after allogeneic bone marrow transplantation. Blood 80:1437, 1992.
20 Higano CS, Chielens D, Raskind W, Bryant E, Flowers ME, Radich J,
Clift R, Appelbaum F: Use of alpha-2a-interferon to treat cytogenetic
relapse of chronic myeloid leukemia after marrow transplantation.
Blood 90:2549, 1997.
21 van Rhee F, Lin F, Cullis J, Spencer A, Cross N, Chase A, Garicochea
B, Bungey J, Barrett J, Goldman J: Relapse of chronic myeloid leukemia
after allogeneic bone marrow transplant: the case for giving donor
leukocyte transfusions before the onset of hematologic relapse. Blood
83:3377, 1994.
22 Roth M, Antin J, Ash R, Terry V, Gotlieb M, Silver S, Ginsburg D:
Prognostic significance of Philadelphia chromosome-positive cells
detected by the polymerase chain reaction after allogeneic bone marrow
transplant for chronic myelogenous leukemia. Blood 79:276, 1992.
23 van Rhee F, Lin F, Cross NC, Reid CD, Lakhani AK, Szydlo RM,
Goldman JM: Detection of residual leukaemia more than 10 years after
allogeneic bone marrow transplantation for chronic myelogenous
leukaemia. Bone Marrow Transplant 14:609, 1994.
24 Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad
F, Castro-Malaspina H, Childs B, Gillio A, Kernan N, Small T, Young J,
O’Reilly R: Adoptive immunotherapy evaluating escalating doses of
donor leukocytes for relapse of chronic myeloid leukemia after bone
marrow transplantation: separation of graft-versus-leukemia responses
from graft-versus-host disease. Blood 86:1261, 1995.
25 Jones R, Ambinder R, Piantadosi S, Santos G: Evidence of a graft-ver-
sus-lymphoma effect associated with allogeneic bone marrow transplan-
tation. Blood 77:649, 1991.
26 Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L,
Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK
gene transfer into donor lymphocytes for control of allogeneic graft-
versus-leukemia. Science 276:1719, 1997.
27 Link CJ Jr, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy
JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, Horowitz M,
Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Fur-
tado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH: Adoptive
immunotherapy for leukemia: donor lymphocytes transduced with the
herpes simplex thymidine kinase gene for remission induction. HGTRI
0103. Hum Gene Ther 9:115, 1998.
28 Gallot G, Hallet MM, Gaschet J, Moreau JF, Vivien R, Bonneville M,
Milpied N, Vie H: Human HLA-specific T-cell clones with stable
expression of a suicide gene: a possible tool to drive and control a graft-
versus-host- graft-versus-leukemia reaction? Blood 88:1098, 1996.
29 Johnson B, Drobyski W, Truitt R: Delayed infusion of normal donor
cells after MHC-matched bone marrow transplantation provides an
antileukemia reaction without graft-versus-host disease. Bone Marrow
Transplant 11:329, 1993.
30 Barrett A, Mavroudis D, Molldrem J, Read E, Carter C, Dunbar C,
Young N: Optimizing the dose and timing of lymphocyte add-back in
Long-term Follow-up After DLI
261B B & M T
T-cell depleted BMT between HLA-identical siblings. Blood 88:460a,
1996.
31 Porter D, Connors J, VanDeerlin V, Duffy K, McGarigle C, Saidman
S, Leonard D, Antin J: A pilot trial of donor leukocyte infusions as pri-
mary adoptive immunotherapy for patients with malignancies. J Clin
Oncol, in press
32 Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P,
O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran
M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian
H, Champlin R: Engraftment of allogeneic hematopoietic progenitor
cells with purine analog-containing chemotherapy: harnessing graft-
versus-leukemia without myeloablative therapy. Blood 89:4531, 1997.
33 Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G,
Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C,
Bel-Tal O, Eldor A, Or R: Nonmyeloablative stem cell transplantation
and cell therapy as an alternative to conventional bone marrow trans-
plantation with lethal cytoreduction for the treatment of malignant and
nonmalignant hematologic diseases. Blood 91:756, 1998.
